Public Summary
Investigational Drug Steering Committee
Tuesday-Wednesday, March 23-24th (2010)

1. **Call to Order, Announcements, and Review of Minutes**
    a. **Review of Minutes:** The IDSC approved the January 15, 2010 meeting minutes.
    b. **CTEP update:**
        i. Dr. James Zwiebel discussed the update to the CTEP LOI template form based on an IDSC suggestion for appeals process.
        ii. NCI Experimental Therapeutics Program (NeXT) has approved a new agent (*name is confidential*).
    c. **CCCT update:**
        i. Dr. Michael Grever will be ending his IDSC U01 co-chair term on January 1, 2011; LeeAnn Jensen will request nominations for a new co-chair from U01 PIs by June-July 2010.
        ii. Amy Gravell will work on scheduling IDSC 2011 meetings.
2. **Open Discussion of New Agents/Targets to Bring into CTEP Portfolio** *(Sullivan):*
    a. Dr. Dan Sullivan and other IDSC members discussed new agents/targets (HDM2, MDM2, and hypoxia) to bring into the CTEP portfolio.
3. **Clinical Proteomics Technologies for Cancer (CPTC):** Dr. Mehdi Mesri provided a detailed overview of the CPTC to IDSC members and summary is listed below.
    a. **Mission Statement of the CPTC**: The NCI CPTC initiative seeks to foster the building of an integrated foundation of proteomic technologies, data, reagents and reference materials, and analysis systems to systematically advance the application of protein science to accelerate discovery and clinical research in cancer.
    b. CPTC and its programs now seek to collaborate with IDSC, SPORES, and Cancer Centers in areas of mutual interest.
    c. Can assist with multiplex assays for measuring analytes that are modified by agent or pathway activity. Ideal for candidates for which there are no antibodies available for immunoassay.
    d. Welcomes opportunities to identify and develop assays and reagents for preclinical and early phase trials. Verified MRM assays developed in CPTC can be forwarded for potential as clinical candidates.
    e. Antibodies produced by CPTC can be used to develop immunoassays for biomarker candidates that come out of programs.
    f. **Contacts:**
        i. Henry Rodriguez, PhD, MBA: rodriguezh@mail.nih.gov 301-451-8883
        ii. Mehdi Mesri, PhD: mesrim@mail.nih.gov 301-451-8883
4. **Cardiovascular Toxicities Panel (CTP) Update:** Dr. Michael Maitland provided an update on the activities of the Cardiovascular Toxicities Panel (CTP) convened by the Angiogenesis Task Force.
    a. **Mission**:
        i. To bring together experts in management of cardiovascular diseases and oncologists to discuss shared concerns of toxicities of kinase inhibitor and VEGF inhibition therapy

ii. To report to ATF/IDSC on state of science in understanding mechanisms of adverse events, recommend areas for further research, provide guidance on standardized management of toxicities in clinical trials.

b. **Blood Pressure Consensus manuscript (project # 1):** This manuscript will be published by Oxford Journals in the Journal of the National Cancer Institute around April 2010 (*lead by Dr. Michael Maitland*).
   i. Article will have open access
   ii. Expect co-authors to write related articles?
   iii. Future reconvening?

c. **Cardiac Toxicities Focus (project # 2):** This manuscript is under final revision at present by CTP panel members. Recommendations to be presented and reviewed by IDSC for approval on a teleconference or at the Monday, July 19th (2010) IDSC meeting in Chicago, IL.

5. **Metrics WG Career Development LOI (CRDL) Survey Results:** Deborah Collyar, WG chair presented the Metrics WG CRDL LOI survey results. The survey revealed that CTEP young investigators would like to meet at ASCO and/or ASH to discuss proper development of letters of intent (LOIs). Additional means of advertising this CTEP session at these national meetings will be sought by NCI and the IDSC.
6. **IDSC Discussion regarding CTCAE 4.0 Conversion (***Shanda Finnigan***):**

October 1, 2009	AdEERS and CDUS ready to accept data in CTCAE v4.0 for new studies.
October 1, 2009	All protocols with a current CTEP status of In Review or Approved on October 1, 2009 will automatically be assigned to CTCAE v4.0 regardless of when they were originally submitted to CTEP for review.
October 1, 2009	Term-to-Term mapping document available. Term/Grade-to-Term/Grade mapping document to follow shortly.
January 1, 2010 – September 30, 2011	Conversion of ongoing studies to CTCAE v4.0.
March 31, 2010	End of CTEP support for ongoing data collection in CTC v2.0. No patient data collected after March 31, 2010 will be accepted in CTC v2.0 by CTEP.
April 1, 2010	All former CTC v2.0 protocols will be switched to CTCAE v4.0 for AdEERS reporting.
September 30, 2011	End of CTEP support for ongoing data collection in CTCAE v3.0. No patient data collected after September 30, 2011 will be accepted in CTCAE v3.0 by CTEP. See the detailed discussion below for direction on how/when to submit the final CTCAE v3.0 CDUS report.
October 1, 2011	Conversion complete. All AdEERS reporting on all protocols will occur in CTCAE v4.0 from this date forward.

7. **Discussion of Increasing U01/N01 Efficiency and Effectiveness (***Pat LoRusso***):** The IDSC formed a LOI Working Group to assess and form recommendations to improve the efficiency of LOIs from phase I U01 and phase II N01 grantees/contractors.
   a. **Motion from LOI Review WG**: In an effort to improve the efficiency of the drug development process, the LOI Review WG has recommended that CTEP will pre-select a designated number of study ideas or concepts for which U01/N01 holders can express

interest and prepare a brief one page LOI submission. A mapping/assignment process will be devised to ensure equitable distribution of LOIs to U01/N01 holders. A comprehensive LOI will be required prior to final approval by CTEP. Following pre-solicitation activities, a mass solicitation may be sent out requesting alternative concepts (full LOI submission needed). In the interest of improving investigational drug access for cancer patients, CTEP will utilize all available resources.

b. The motion was passed by the IDSC with a secret ballot vote.

8. **DCTD PD Biomarker Update: Dr.** Joe Tomaszewski presented the status of the DCTD PD Biomarker portfolio to IDSC members. More information can be found at this website: http://dctd.cancer.gov/ResearchResources/ResearchResources-biomarkers.htm
9. **OSI-906 Update:** The CRADA for OSI-906 may move forward and the IDSC thought that the Signal Transduction Task Force should re-review (originally reviewed in March 2009) the CTEP clinical development plan prior to a CTEP mass solicitation.
10. **Future Calls/Meetings/Plans**
    a. Next call: TBD
    b. IDSC Summer 2010 meeting: Monday, July 19th (Chicago, IL)
    c. EDD/IDSC Fall 2010 meeting: Monday-Wednesday, September 27-29, 2010 (Bethesda)

ATTACHMENT 1

Agent Name	Inhibits	IDSC Review	Mass Solicitation Status?
IMC-A12	IGF-1R	September 2006	Issued
IL-12	immune regulation	July 2008	Issued
SCH727965	cdk	February 2008	Issued
GDC-0449	sonic hedgehog	November 2008	Issued
RO4929097	notch	January 2009	Issued
OSI-906	IGF-1R	March 2009	Pending
MK-2206	akt	March 2009	Issued
ABT-263	bcl2, BH3 mimetic	April 2009	Issued
AZD8055	mTOR	May 2009	ON-HOLD
ARQ-197	cMet	October 2009	Pending
SCH900105	cMet	October 2009	Pending
MK-8033	cMet	October 2009	ON-HOLD
AT13387	HSP90	Ocotber 2009	ON-HOLD